<DOC>
	<DOCNO>NCT02134405</DOCNO>
	<brief_summary>This multi-Asian-centre randomise control trial Rebamipide alone vs Rebamipide Esomeprazole treatment adult patient Functional Dyspepsia . The hypothesis combination therapy superior mono-therapy control patient ' symptom quality life improvement .</brief_summary>
	<brief_title>Rebamipide Combination With Esomeprazole Management Asian Patients With Functional Dyspepsia</brief_title>
	<detailed_description>Primary Objective : To assess efficacy Rebamipide combination Esomeprazole improvement symptom Functional Dyspepsia Asian patient compare Esomeprazole alone Secondary Objective : . To assess efficacy Rebamipide combination Esomeprazole improvement quality life Asian patient Functional Dyspepsia compare Esomeprazole alone ii . To assess cost-effectiveness Rebamipide combination Esomeprazole compare Esomeprazole alone 8 , 12 week treatment iii . To assess safety Rebamipide combination Esomeprazole adult functional dyspepsia 8 week treatment . Trial Design Multi-national , randomise , double-blind , placebo-controlled study Treatment Group : - Study Group : Rebamipide + Esomeprazole - Control Group : Rebamipide placebo + Esomeprazole Investigational Product ( IP ) : Rebamipide 100 mg tablet Rebamipide placebo tablet Esomeprazole 20 mg tablet Dosage regimen : Administration route : PO Rebamipide 100 mg t.i.d Rebamipide placebo t.i.d Esomeprazole 20 mg o.d Target Population Male female subject age 18 year less 80 year diagnose Functional Dyspepsia ( FD ) Primary Endpoint : Change Leeds Dyspepsia Questionnaire ( LDQ ) total score baseline 8 week treatment Secondary Endpoints : 1 . The change Health-Related Quality Life ( EQ-5D ) baseline 8 week treatment 2 . The cost effectiveness base cost per QALY gain study group compare control group 8 , 12 week 3 . The change Leeds Dyspepsia Questionnaire ( LDQ ) total score Health-Related Quality Life ( EQ-5D ) baseline 12 week Inclusion Criteria : 1 . Patients diagnose Functional Dyspepsia use Rome III diagnostic criterion 2 . Age ≥ 18 year , &lt; 80 year 3 . Subject ability provide write informed consent willingness comply requirement protocol 4 . Able communicate English , Malay Mandarin languages 5 . Patients prior dyspepsia treatment - washout period 1 week Exclusion Criteria : 1 . Patients know hypersensitivity Rebamipide and/or Esomeprazole component formulation . 2 . Pregnant , nursing , childbearing potential woman unwilling effective contraception ; example , oral contraceptive , hormonal method , placement intrauterine device ( IUD ) intrauterine system ( IUS ) , barrier method ( i.e. , condom occlusive cap spermicidal foam/gel/film/cream/ suppository ) , male sterilization , true abstinence 3 . Presence family history GI malignancy alarm feature suggest malignancy - e.g . Unintentional weight loss ( 10 % body weight recent 6 month ) , GI bleed 4 . Patients consume regular Aspirin NSAIDs ( except low-dose Aspirin dose 325 mg/day less cardiovascular prophylaxis ) 5 . History erosive esophagitis , peptic ulcer disease within 1 year prior screen 6 . History gastrointestinal ( GI ) malignancy , primary esophageal motility disorder , document upper GI surgery 7 . Patients hepatobiliary pancreatic disease 8 . Patients severe depression , anxiety , psychological disorder 9 . Patients terminal disease 10 . Presence irritable bowel syndrome ( Rome III criterion ) inflammatory bowel disease ( IBD ) 11 . Necessary continuous concomitant treatment sucralfate , quinidine , warfarin , phenytoin , bisphosphonates , methotrexate , ketoconazole , fluconazole , itaconazole , diazepam , anti-cholinergics , H2RAs , PPIs ( except study drug ) , prokinetics , and/or NSAIDs ( except topical use NSAIDs ; systemic NSAIDs ≤2 days/week ) 12 . Use PPIs ( except study drug ) , H2RAs , prokinetics , antibiotic ( except topical use ) , misoprostol , bismuth compound within 1 week prior screening , take antibiotic use eradicate Helicobacter pylorus within 4 week prior screen 13 . Unable communicate English , Malay , Mandarin 14 . Other condition determine investigator inappropriate clinical study Duration treatment : 8 week Number subject : Ninety-three patient per group 90 % power 0.05 significance level use . Considering 10 % drop-out rate , total 208 patient ( 104 patient per group ) enrol study . Total : 208 Study Group : 104 Control Group : 104 Anticipated Timelines : Duration trial : 18 month Start recruitment : March 2014 End recruitment : August 2015 Last subject : Oct 2015 Statistical Methodology : Primary Endpoint Change Leeds Dyspepsia Questionnaire ( LDQ ) total score baseline 8 week treatment Secondary Endpoint 1 . The change Health-Related Quality Life ( EQ-5D ) baseline 8 week treatment 2 . The cost effectiveness base cost per QALY gain study group compare control group 8 , 12 week 3 . The change Leeds Dyspepsia Questionnaire ( LDQ ) total score Health-Related Quality Life ( EQ-5D ) baseline 12 week Summary statistic endpoint provide . Mean change evaluate two sample t-test Wilcoxon 's rank sum test accord normal distribution analyze variable . Safety Endpoint 1 . Adverse event The number case AEs proportion patient experience AEs summarize descriptive statistic ( frequency proportion ) study group . 2 . Laboratory Test Vital Signs All laboratory value vital sign compare within study group study group .</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>1 . Patients diagnose Functional Dyspepsia use Rome III diagnostic criterion 2 . Age ≥ 18 year , &lt; 80 year 3 . Subject ability provide write informed consent willingness comply requirement protocol 4 . Able communicate English , Malay Mandarin languages 5 . Patients prior dyspepsia treatment washout period 1 week 1 . Patients know hypersensitivity Rebamipide and/or Esomeprazole component formulation . 2 . Pregnant , nursing , childbearing potential woman unwilling effective contraception ; example , oral contraceptive , hormonal method , placement intrauterine device ( IUD ) intrauterine system ( IUS ) , barrier method ( i.e. , condom occlusive cap spermicidal foam/gel/film/cream/suppository ) , male sterilization , true abstinence 3 . Presence family history GI malignancy alarm feature suggest malignancy e.g . Unintentional weight loss ( ≥ 10 % body weight recent 6 month ) , GI bleed 4 . Patients consume regular Aspirin NSAIDs ( except lowdose Aspirin dose 325 mg/day less cardiovascular prophylaxis ) 5 . History erosive esophagitis , peptic ulcer disease within 1 year prior screen 6 . History gastrointestinal ( GI ) malignancy , primary esophageal motility disorder , document upper GI surgery 7 . Patients hepatobiliary pancreatic disease 8 . Patients severe depression , anxiety , psychological disorder 9 . Patients terminal disease 10 . Presence irritable bowel syndrome ( Rome III criterion ) inflammatory bowel disease ( IBD ) 11 . Necessary continuous concomitant treatment sucralfate , quinidine , warfarin , phenytoin , bisphosphonates , methotrexate , ketoconazole , fluconazole , itaconazole , diazepam , anticholinergic , H2RAs , PPIs ( except study drug ) , prokinetics , and/or NSAIDs ( except topical use NSAIDs ; systemic NSAIDs ≤2 days/week ) 12 . Use PPIs ( except study drug ) , H2RAs , prokinetics , antibiotic ( except topical use ) , misoprostol , bismuth compound within 1 week prior screening , take antibiotic use eradicate Helicobacter pylorus within 4 week prior screen 13 . Unable communicate English , Malay , Mandarin 14 . Other condition determine investigator inappropriate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>functional dyspepsia</keyword>
	<keyword>symptom</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>gastritis</keyword>
</DOC>